Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jan 25;18(1):e0280778. doi: 10.1371/journal.pone.0280778

The Q163C/Q309C mutant of αMI-domain is an active variant suitable for NMR characterization

Hoa Nguyen 1, Tianwei Jing 2, Xu Wang 1,*
Editor: Matteo De March3
PMCID: PMC9876370  PMID: 36696377

Abstract

Integrin αMβ2 (Mac-1, CD11b/CD18, CR3) is an important adhesion receptor expressed on monocytes. Mac-1 is responsible for mediating cell migration, phagocytosis, degranulation as well as cell-cell fusion. It is also the most promiscuous integrin in terms of ligand specificity with over 100 ligands, most of which use the αMI-domain as their binding site. Despite the importance of αMI-domain in defining ligand interactions of Mac-1, structural studies of αMI-domain’s interactions with ligands are lacking. In particular, solution NMR studies of αMI-domain’s interaction with ligands have not been possible because the most commonly used active αMI-domain mutants (I316G and ΔK315) are not sufficiently stable and soluble to be used in solution NMR. The goal of this study is to identify an αMI-domain active mutant that’s amenable to NMR characterization. By screening known activating mutations of αMI-domain, we determined that the Q163C/Q309C mutant, which converts the αMI-domain into its active form through the formation of an intramolecular disulfide bond, can be produced with a high yield and is more stable than other active mutants. In addition, the Q163C/Q309C mutant has better NMR spectral quality than other active mutants and its affinity for ligands is comparable to other active mutants. Analysis of the Co2+-induced pseudocontact shifts in the Q163C/Q309C mutant showed the structure of the mutant is consistent with the active conformation. Finally, we show that the minor fraction of the Q163C/Q309C mutant without the disulfide bond can be removed through the use of carboxymethyl sepharose chromatography. We think the availability of this mutant for NMR study will significantly enhance structural characterizations of αMI-domain-ligand interactions.

Introduction

Integrins are heterodimeric adhesion receptors ubiquitous to all metazoans [1]. Integrins play vital roles in numerous cellular processes including cell growth, proliferation, differentiation, and migration. In the cells of the innate immune system, integrins are also responsible for the phagocytosis of opsonized targets as well as fusion with other immune cells [2, 3]. Much of integrins’ activities depend on their ability to bind specifically to extracellular proteins. As a result, ligand specificities of integrins are vital determinants of their activities, and understanding the ligand binding mechanisms behind these specificities is an essential step in the development of therapies targeting integrins.

All integrins contain an α and a β subunit. Humans have 18 different α subunits and 8 different β subunits. The selective pairing of these subunits produces 24 unique integrin receptors in humans. Different integrins recognize different ligands [4]. The ligand specificity of the myeloid cell integrin αMβ2 (Mac-1, CD11b/CD18, CR3) is especially interesting. Mac-1 is expressed primarily on myeloid cells such as neutrophils and macrophages. It is involved in the phagocytosis of opsonized particles, cell-cell fusion, and acts as an important regulator of the immune activities of these cells [5]. Its ligand specificity is also the broadest among all integrins. So far, more than 100 ligands have been reported to bind to Mac-1 [2]. Mac-1 ligands vary greatly in chemical structure and physical properties. However, the binding site for the vast majority of ligands is located in the I-domain of Mac-1’s αM subunit (αMI-domain). Despite the importance of αMI-domain in ligand binding, only the structure of αMI-domain with one of its natural ligands, the complement fragment iC3b, is determined [6, 7]. The mechanism by which αMI-domain recognizes most other ligands remains unknown [2, 3]. An important factor contributing to the lack of understanding of αMI-domain’s ligand specificity is the absence of an appropriate active αMI-domain variant suitable for solution NMR characterization, a major tool for structural biologists.

αMI-domain is a ~ 200 residue domain with a Rossmann fold. The apical side of the domain contains a metal-binding site capable of chelating divalent cations such as Mg2+, Ca2+, Co2+, and Mn2+. These metals are usually crucial mediators of ligand binding. As a result, the metal-binding site is referred to as the metal ion-dependent adhesion site (MIDAS). Similar to other integrins, Mac-1 can adopt both inactive and active conformations. In the active conformation, the C-terminal α7 helix of αMI-domain is pulled away from the MIDAS, causing the metal ion coordination to change. This allows the metal ion to be coordinated by acidic amino acids on the ligand, thereby greatly increasing the affinity of the domain for its ligands [8]. Because of active αMI-domain’s higher affinity for ligands, most structural biology studies of αMI-domain’s interactions with ligands use active αMI-domain. These active forms are generated from wild type, inactive αMI-domain by pulling the C-terminal helix away from the MIDAS using several methods. The most popular method is to either mutate residue I316 to Gly (I316G) or to truncate the C-terminal α7 helix at residue K315 (ΔK315) [8, 9]. This method disrupts the hydrophobic interactions that hold the α7 helix in place, allowing the domain to adopt the active conformation. Although these mutants have been successfully used in X-ray crystallography studies of αMI-domain’s interactions with ligands [68, 10], there is no report on the suitability of these active mutants for use in solution NMR studies.

In this study, we show that both the I316G mutation and truncation at K315 lead to significant destabilization of αMI-domain, resulting in lower protein yield, lower solubility and lower NMR signal intensities. These disadvantages made solution NMR characterizations of αMI-domain’s ligand interactions difficult. To explore the suitability of other active αMI-domain mutants for NMR studies, we examined three other active mutants. Unlike the I316G and ΔK315 mutants, these mutants force the αMI-domain into the active conformation by constraining the position of the α7 helix using disulfide bonds. In particular, McCleverty and Liddington reported that the addition of the intramolecular disulfide bond in the mutant D132C/K315C enhanced its affinity for the ligand ICAM1 [11]. Shimaoka et al. also reported that the mutations Q163C/Q309C, and D294C/Q311C in αM increased Mac-1-expressing HEK293T cells’ affinity for iC3b in HEK293T cells [12] (see Fig 1 of S1 Fig for the positions of the cysteine mutations). However, no structural studies were done to confirm these αMI-domain mutants were in the active form. We hypothesize that, by not disrupting the hydrophobic core, these active mutants should be more stable and more amenable to structural characterization by solution NMR. To confirm this hypothesis, we expressed and purified all three mutants and characterized them using NMR, SPR, and other biophysical techniques. Our results show that only one of the mutants (Q163C/Q309C) can spontaneously form the required disulfide bond. Although treatment of the D132C/K315C mutant with the oxidizing agent Cu2+/phenanthroline was reported to produce active forms of the mutant, our data indicate only ~ 50% of protein were disulfide bonded after the treatment while unintended modifications associated with oxidations of other amino acids also took place. In addition, expressing the Q163C/Q309C mutant in the E. coli strain OrigamiB(DE3), which contains lower levels of the reductants glutathione and thioredoxin, further improved the percentage of proteins with the internal disulfide bond from ~ 90% to ~ 95%. More importantly, the Q163C/Q309C mutant has better yield, higher thermal stability, and better NMR spectral quality. Analysis of Co2+-induced pseudocontact shifts (PCS) of the Q163C/Q309C mutant showed the structure of the mutant is consistent with the active conformation. SPR analysis also showed that the Q163C/Q309C mutant has a similar affinity for the ligand C3d as the I316G and ΔK315 mutants. Finally, the small fraction of protein without the intramolecular disulfide bond can be easily removed by taking advantage of the high affinity of the active αMI-domain for carboxymethyl dextran. In sum, these results show the Q163C/Q309C mutant is excellent for NMR studies. We think this mutant will be useful to researchers interested in studying the interactions of αMI-domain with its ligands.

Materials and methods

Expression and purification of αMI-domain

The expression and purification of αMI-domain followed the procedures in Feng et al. [13]. Briefly, the open reading frame (ORF) of the wild type human αMI-domain (E131-T324) was cloned into the pHUE vector [14] using SacII and HindIII as restriction sites. Cysteine mutations (Q163C/Q309C, D132C/K315C, D294C/Q311C) were introduced into αMI-domain using the Q5 Site-Directed Mutagenesis Kit (NEB). The plasmids were transformed into either BL21(DE3) or OrigamiB(DE3) (Millipore Sigma) and the cells were grown in M9 media at 37°C until the culture reached an OD600 of ~ 0.8–1. The protein expression was induced with 0.5 mM IPTG, and cells were harvested after overnight incubation at 22°C. Cells were lysed with sonication after a 20-minute incubation on ice in a buffer containing 20 mM sodium phosphate, pH 7, 0.5 M NaCl, 10 mM imidazole, 5% glycerol, and 1 mg/ml lysozyme. After centrifugation to remove insoluble material, the supernatant was passed through a 5-mL HisTrap column (Cytiva) and the protein was eluted with a 0.01 to 0.5 M gradient of imidazole. To separate the N-terminal His-Ubiquitin from αMI-domain, the protein was digested with enzyme USP2 (1:50 molar ratios) overnight at room temperature in 20 mM Tris, pH 8, 100 mM NaCl. The digestion mixture was then subjected to Ni2+ column purification again. αMI-domain in the flow through was further purified using a 120-mL Superdex 75 column equilibrated in buffer containing 20 mM HEPES, 0.3 M NaCl, pH 7.0. Finally, the protein was exchanged to 20 mM HEPES, 100 mM NaCl, pH 7.0 for thermal shift and NMR analyses. SPR analysis was carried out in 20 mM HEPES, pH 7 buffer containing 0.1 M NaCl, 1 mM MgCl2, and 0.05% Tween 20. 15N, 13C, and 2H isotope enrichment was accomplished using 15N-enriched NH4Cl, 2H,13C-enriched glucose, and D2O. In particular, OrigamiB(DE3) cells freshly transformed with the expression plasmid for the Q163C/Q309C mutant was first grown in LB at 37°C until an OD600 of ~1.0. 2 mL of the culture was then pelleted gently at room temperature and used to seed 50 mL of 2H,13C,15N-enriched minimal media containing 4 g/L of 2H,13C-glucose. The culture was grown overnight at 37°C and diluted with 450 mL of fresh 2H,13C,15N-enriched minimal media. The large scale culture was grown to an OD600 of ~ 0.8 to 1.0 and induced with 0.5 mM of IPTG. The culture was then placed in an shaker incubator at 22°C for 18 hours before being harvested.

Expression and purification of C3d

C3d was expressed and purified according to Bajic et al. [6]. Briefly, ORF of C3d (residues 993 to 1288) was cloned into pET15b with 6XHis and TEV cleavage site at the N-terminus and expressed in E. coli BL21(DE3) using a similar procedure as αMI-domain. Specifically, after harvesting, cells were resuspended in 20 mM Tris, 200 mM NaCl, pH 8.0 in addition to 1 mg/mL lysozyme. The supernatant after sonication was passed through a 5-ml HisTrap column (Cytiva) and the protein was eluted using a 0.01 to 0.5 M imidazole gradient. The chimera protein was digested with TEV protease with a protein-to-enzyme ratio of 50. The digested protein was subjected to a second Ni2+-affinity column. Flow through fractions containing C3d were combined and concentrated.

Protein thermal shift assay of αMI-domain

To measure the thermal stability of αMI-domain, 10 μg of αMI-domain in 12.5 μL of 20 mM HEPES, 0.1 M NaCl, pH 7 buffer were mixed with 2.5 μL of 8X protein thermal shift dye (Thermo Fisher Scientific), and 5 μL of 4X protein thermal shift assay buffer (Thermo Fisher Scientific). Duplicates of each sample were heated from 22°C to 99°C with a temperature gradient of 0.015°C / second in a QuantStudio 3 qPCR instrument. The fluorescence of the samples was measured using an excitation wavelength of 580 nm and an emission wavelength of 623 nm.

SPR analysis of αMI-domain’s interaction with C3d

SPR analysis was carried out on a BI-4500 SPR instrument (Biosensing Instrument). To carry out the measurement, 50 μM C3d was flowed at a rate of 20 μL/min over EDC/NHS-activated CM-dextran sensor until a response of ~ 1000 RU was observed. An increase of 1 RU corresponds to protein deposition of ~ 1 pg / mm2. After washing with 1.5 M NaCl, wild type, ΔK315, I316G, and Q163C/Q309C αMI-domain at concentrations of 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, and 12.5 μM were flowed over the sensor while data were acquired. The sensor was regenerated with 1.5 M NaCl after each sample. Response curves were background corrected by subtracting the response of the reference channel with no immobilized C3d.

NMR data collection and analysis

NMR data were acquired on a Bruker 600 MHz instrument equipped with Avance III HD console and a Prodigy probe. All NMR samples contained 0.1 to 0.3 mM 15N-labeled αMI-domain in 20 mM HEPES, 0.1 M NaCl, pH 7.0 buffer. To study the effect of Mg2+ and glutamate on the protein, 1 mM MgCl2 and 10 mM sodium glutamate were also included in the sample. 15N-edited HSQC spectra were acquired using the Bruker pulse sequence fhsqcf3gpph. Pseudocontact shifts (PCS) were measured by comparing the amide hydrogen chemical shifts of the 2H/13C/15N-labeled Q163C/Q309C mutant in the Co2+-bound form with the Mg2+-bound form. PCS samples also contained 10 mM glutamate to prevent aggregation of the protein. Backbone amide hydrogen and nitrogen assignments were obtained using information from HNCACB and HNCOCAB spectra for both Co2+- and Mg2+-bound proteins. To assign the chemical shifts of the Mg2+ species, we first tabulated the HN, N, CA, CB chemical shifts as well as CA and CB chemical shifts of the previous amino acids for each spin system using the spectral data. The information was then used to derive possible assignment using iPINE [15]. Each assignment was then examined manually to confirm the assignment. Similarly, we tabulated the HN, N, CA, CB chemical shifts as well as CA and CB of the previous amino acids for each spin system in the Co2+ data. Then, utilizing the fact that PCS of backbone amide H and N are similar if the atoms are not too close to the paramagnetic center, possible assignments were proposed by finding assigned signals that are shifted diagonally in the HSQC spectrum of Mg2+ sample. The possible assignments were further validated by comparing the CA and CB chemical shifts of the Co2+ and Mg2+ samples, taking into consideration that CA and CB chemical shifts may have PCS of similar magnitudes. The preliminary PCS tensor calculated using these assignments were used to predict additional assignments. NMR data were processed using NMRPipe [16] and analyzed using NMRViewJ [17]. Fitting of PCS to the structures of active and inactive αMI-domain (PDB ID 1IDO and 1JLM) was carried out using the software Paramagpy [18]. The quality factor of fitting is defined as i(aiexpaical)2i(aiexp)2, where aiexp and aical are the experimental and calculated PCS for atom i. Chemical shift assignments of the Mg2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51714. Chemical shifts for the Co2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51716.

Results

Spontaneous disulfide bond formation in mutants

Our study is motivated by a desire to study the ligand specificity of αMI-domain using solution NMR. In our hands, both the ΔK315 mutant (residues E131 to K315) and the I316G mutant showed low solubility and poor NMR spectral quality (vide infra). We attribute this to the fact that the disruption of the hydrophobic core of αMI-domain may have significantly destabilized the protein, rendering them unsuitable for solution NMR studies. Fortunately, activation of αMI-domain using constraining disulfide bonds that pull the C-terminal α7 helix away from MIDAS has also been reported. We recombinantly expressed three such mutants. These mutants are D132C/K315C [11], Q163C/Q309C [12], and D294C/Q311C [12]. Of these three mutants, D132C/K315C has been shown to have a higher affinity for ICAM1 after treatment with an oxidizing agent whereas HEK293T cells expressing the Q163C/Q309C, and D294C/Q311C Mac-1 mutants achieved higher ligand affinity even without oxidizing treatments [12]. We recombinantly expressed all three mutants in E. coli BL21(DE3). Analysis of the purified proteins using SDS-PAGE under reducing and non-reducing conditions revealed that the formation of the intramolecular disulfide bond significantly increased the migration distance of the protein in SDS-PAGE. This provided us with a simple method to determine the fraction of proteins containing the intramolecular disulfide bond. Fig 1A shows SDS-PAGE analysis of the three mutants in the presence and absence of 1 mM DTT. It is clear that neither the D132C/K315C nor the D294C/D311C mutant was able to form a significant amount of the intramolecular disulfide bond while close to 90% of the Q163C/Q309C mutant did. In addition, both the D132C/K315C and the D294C/D311C mutants produced a detectable amount of dimer as a result of intermolecular disulfide bonding, but no dimer was observed in the Q163C/Q309C mutant.

Fig 1. Expression of internally disulfide bonded mutants of αMI-domain.

Fig 1

A) The SDS-PAGE analysis of three disulfide bond mutants produced in BL21(DE3) and the effect of DTT on their migration. B) The SDS-PAGE analysis of the effect of 0.1 μM Cu2+/phenanthroline complex, 1 mM Mg2+, and 10 mM glutamate on the formation of the intramolecular disulfide bond in the D132C/K315C mutant. C) SDS-PAGE analysis of the Q163C/Q309C mutant produced in BL21(DE3) and OrigamiB(DE3).

Because it was reported that the intramolecular disulfide bond in the D132C/K315C mutant only forms after the protein was treated with 0.1 μM Cu2+/phenanthroline complex [11], we examined the efficiency of such a process. Besides 0.1 μM of Cu2+/phenanthroline, we also tested the effect of 1 mM MgCl2 and 10 mM sodium glutamate on the efficiency of disulfide bond formation since these compounds are ligands of active αMI-domain [19] and may stabilize the active conformation. Fig 1B shows the result of the experiment. Not surprisingly, 1 mM MgCl2 and 10 mM sodium glutamate had little effect on the formation of the intramolecular disulfide bond by themselves, but when used in combination with 0.1 μM Cu2+/phenanthroline, they increased the fraction of the proteins with the intramolecular disulfide bond to ~ 50%. However, many other minor bands as well as a band corresponding to the dimer were also visible. We think the minor bands may be produced by the oxidation of other amino acids by Cu2+. Interestingly, the original study of the D132C/K315C mutant noted that the protein could not be successfully crystallized [11]. This may be a consequence of the heterogeneous oxidation of the protein.

Because the intramolecular environment of E. coli is reducing and not conducive to the formation of disulfide bonds, we also examined whether the engineered E. coli strain OrigamiB(DE3), which contains mutations in its genes for glutathione reductase and thioredoxin reductase, can produce more proteins with the intramolecular disulfide bond. Fig 1C shows the SDS-PAGE of the Q163C/Q309C mutant produced in BL21(DE3) and OrigamiB(DE3). Densitometry analysis of band intensities showed the OrigamiB(DE3) strain modestly improved the amount of protein with the intramolecular disulfide bond from ~ 90% to ~ 95%.

Yield and thermal stability of active mutants

Compared with the I316G and ΔK315 mutants, the yield of Q163C/Q309C mutant is significantly higher. Fig 2A shows the final Superdex 75 chromatograms of Q163C/Q309C, I316G, and ΔK315 mutants. Based on the area under the elution peak, we estimate the yield of the Q163C/Q309C mutant was ~ 3.5 times that of the I316G and ΔK315 mutants (382 mAU*mL/L for the Q163C/Q309C mutant vs 90 mAU*mL/L for ΔK315 and 87 mAU*mL/L for I316G). BCA assay of the final products showed that the yield of the Q163C/Q309C mutant was ~ 3.8 mg / L whereas the yield for the I316G and ΔK315 mutants was ~ 1.1 mg / L. To compare the stability of active αMI-domain mutants, we carried out differential scanning fluorimetry [20]. The results show that the Q163C/Q309C mutant is significantly more stable than the I316G and ΔK315 mutants. In particular, while the Q163C/Q309C mutant has a melting temperature of ~ 61°C, the melting temperatures of the I316G and ΔK315 mutants were only 48°C and 45°C, respectively. Interestingly, the melting temperature of the Q163C/Q309C mutant is slightly higher than the wild type αMI-domain (58°C). This indicates the disulfide bond adds significant stability to the protein structure.

Fig 2. Comparison of the yield and stability of the active mutants.

Fig 2

A) The final SEC chromatograms of the three active mutants. The chromatograms are proteins from 1 liter of the Q163C/Q309C mutant, 2 liters of the I316G mutant, and 3 liters of the ΔK315 mutant. B) Fluorescence changes in the thermal shift assay of the active mutants. The top panel is the plot of the fluorescence signal against the temperature. The bottom panel is the plot of the derivative of the fluorescence signal with respect to the temperature.

SPR analysis of active αMI-domain’s interaction with C3d

Although HEK293T cells expressing Mac-1 with the Q163C/Q309C mutations were shown to have a higher affinity for ligands than wild type Mac-1 expressing cells [12], there is no biochemical study showing the Q163C/Q309C αMI-domain has enhanced affinity for ligands compared to wild type I-domain. To confirm that the Q163C/Q309C mutant indeed has enhanced affinity for ligands, we examined the mutant’s interactions with C3d, the Mac-1-binding domain in complement 3 [6]. Fig 3 shows the SPR sensorgrams for the αMI-domain variants flowed over a sensor with immobilized C3d. Fitting the equilibrium portions of these sensorgrams to a one-to-one binding model showed that, Q163C/Q309C, ΔK315, and I316G mutants all have dissociation constant of binding (Kd) in the 0.5 to 1 μM range, similar to those reported in other studies [6, 7]. These results indicate the Q163C/Q309C mutant has a similar affinity for C3d as other active mutants. However, it is notable that the koff rate of ΔK315 appears to be slower than the other two active mutants, implying the kinetics of binding differ slightly among the mutants. Control experiments carried out using inactive αMI-domain showed inactive αMI-domain does not have a measurable affinity for C3d (Fig 2 of S1 Fig).

Fig 3. SPR characterization of C3d’s interactions with active αMI-domains.

Fig 3

A) sensorgrams of a C3d-functionalized sensor treated with 0.19, 0.39 0.78, 1.56, 3.13, 6.25, and 12.5 μM of ΔK315, I316G, or Q163C/Q309C mutants. Injection of αMI-domain started at time zero and ended after 180 seconds. B) Estimation of the dissociation constant (Kd) of the interaction for each active αMI-domain by fitting the equilibrium values of the response curves to a one-to-one binding model.

Solution NMR analysis of the Q163C/Q309C mutant

To investigate whether the Q163C/Q309C mutant has better NMR spectral quality than other active mutants, we collected the 15N-edited HSQC spectra of 0.1 mM 15N-labeled ΔK315, I316G, and Q163C/Q309C mutants (Fig 4A). A comparison of the spectra showed the Q163C/Q309C mutant produced significantly higher signal intensities than the other two mutants. In addition, samples of the ΔK315 and I316G mutants showed large signal intensity decreases after 24 hours at room temperature whereas the Q163C/Q309C sample of the same concentration showed no significant change (Fig 4B). These results indicate the Q163C/Q309C mutant is more soluble and stable than the ΔK315 and I316G mutants.

Fig 4. 15N-edited HSQC spectra of active mutants.

Fig 4

A) Comparison of the 15N-edited HSQC spectra of 0.1 mM ΔK315, I316G, and Q163C/Q309C mutants. Spectra were acquired with identical parameters and displayed at the same contour level. B) 1st increment of the 15N-edited HSQC spectra of 0.1 mM ΔK315, I316G, and Q163C/Q309C mutants before (blue) and after (red) a 24-hour incubation at room temperature. C) Effects of 1 mM MgCl2 and 10 mM sodium glutamate on the spectrum of the Q163C/Q309C mutant.

To confirm that the Q163C/Q309C mutant can bind ligands using the metal-mediated mechanism, we also investigated how Mg2+ and glutamate affect the NMR spectrum of the mutant. As shown in Fig 4C, glutamate produced no changes in the HSQC spectrum of the mutant while the addition of MgCl2 reduced the signal intensity without producing new signals. We attribute this to the fact that, in the presence of MgCl2, the active αMI-domain has a significantly higher affinity for carboxyl-containing molecules, and this may have led to the formation of large homo-oligomers that are not detectable by solution NMR. Consistent with this hypothesis is the fact that the presence of both glutamate and MgCl2 resulted in large chemical shift changes and significantly stronger signals. We think this is because glutamate, by acting as the competing ligand, was able to dissociate the homo-oligomers, thereby producing the spectrum of the Q163C/Q309C mutant in the ligand-chelated form.

To verify that the conformation of the Q163C/Q309C mutant is similar to the active αMI-domain and not the inactive αMI-domain, we measured pseudocontact shifts (PCS) induced by the paramagnetic ion Co2+. αMI-domain naturally binds Co2+, and Co2+ does not affect the activity of the protein [21]. This allows the PCS induced by Co2+ to be used to validate the structure of the Q163C/Q309C mutant. PCS arise from the dipole-dipole interactions between a paramagnetic metal ion with an anisotropic magnetic susceptibility tensor and nearby atoms. It is both distance and orientation dependent. As a result, PCS has become a valuable tool in protein structure validation [22]. We assigned some backbone amide hydrogen and nitrogen chemical shifts for both the Co2+ and Mg2+ species of the Q163C/Q309C mutant in the presence of 10 mM glutamate (see Fig 3 of S1 Fig for sample spectral data). In total, 77 out of 186 non-proline residues in the Mg2+ species were assigned. Out of the 77 assigned residues, assignments for 56 of which were made for the Co2+ species. This allowed us to extract 38 backbone amide hydrogen PCS with magnitudes larger than 0.05 ppm (S1 Table). Fitting the PCS values to the active αMI-domain structure (PDB 1IDO) produced a best-fitting magnetic susceptibility tensor with a paramagnetic center less than 0.9 Ǻ away from the position of the metal in the crystal structure (Fig 5). The agreement between experimental and predicted PCS values is also excellent, with a quality factor of 0.04 (Fig 5). However, the same set of PCS did not fit as well to the inactive structure of αMI-domain (PDB 1JLM). In particular, the paramagnetic center of the best-fitting magnetic susceptibility tensor for the inactive structure is more than 7 Ǻ away from the metal in the crystal structure (Fig 5) and the quality factor of fitting was 0.16, significantly larger than that of the fitting to the active structure. These results support the conclusion that the Q163C/Q309C mutant adopts the active conformation.

Fig 5. Consistency of the Q163C/Q309C mutant’s Co2+-induced PCS with crystal structures of active and inactive αMI-domains.

Fig 5

A) Plots of calculated vs experimental PCS. Calculated PCS were predicted from the best-fit magnetic susceptibility tensor obtained using the structure of either active αMI-domain (PDB: 1IDO) or inactive αMI-domain (PDB: 1JLM). B) Ribbon representations of active (tan) and inactive (cyan) αMI-domain with the position of the metal in the crystal structure indicated by a green sphere. The PCS-predicted paramagnetic center indicated by a purple sphere.

Carboxymethyl sepharose purification of the Q163C/Q309C mutant

To provide proteins of the highest purity for structural biology studies, we also devised a strategy to remove the minor population of reduced protein. The method takes advantage of the fact that αMI-domain in the active conformation has a significantly higher affinity for carboxyl-containing amino acids such as glutamate than in the inactive conformation [19]. Based on this, we postulated that carboxymethyl (CM) sepharose chromatography resin may have a higher affinity for the active αMI-domain than the inactive αMI-domain in the presence of MgCl2, thereby separating the active αMI-domain from the inactive αMI-domain. Fig 6A shows the CM column chromatogram of the Q163C/Q309C mutant. The protein was loaded onto the column in 20 mM HEPES, 0.15 M NaCl, and 2 mM MgCl2, pH 7.0. The column was washed with five column volumes of the same buffer after sample application. Finally, the mobile phase was switched to 20 mM HEPES, 0.15 M NaCl, and 10 mM EDTA, pH 7.0. The chromatogram showed that a small peak emerged during sample application while two larger peaks were seen after the application of the EDTA buffer. SDS-PAGE analysis showed that the flow through (FT) peak contained a ~ 50% / 50% mixture of reduced and disulfide bonded species (Fig 6A) whereas the elution peaks contained only the disulfide bonded form of the protein. This result is consistent with our postulate that the active form of the protein has a higher affinity for CM resin in the presence of MgCl2.

Fig 6. CM purification of the Q163C/Q309C mutant.

Fig 6

A) The CM-sepharose chromatogram produced by the Q163C/Q309C mutant and the SDS-PAGE analysis of the flow through and elution fractions. Note that no reducing agent was used in the SDS-PAGE. B) 15N-edited HSQC spectrum of the protein in elution peak 1 before EDTA treatment. C) 15N-edited HSQC spectrum of the protein in elution peak 1 after EDTA treatment. D) 15N-edited HSQC spectrum of the protein in elution peak 2.

We also studied the proteins in the two elution peaks using solution NMR. Surprisingly, the protein in the first elution peak resembled that of the protein in the presence of both MgCl2 and glutamate, signifying that this fraction of the protein may be chelating a carboxyl-containing ligand (Fig 6B). Protein in the second elution peak produced a spectrum identical to that of the apo Q163C/Q309C mutant (Fig 6C). The addition of EDTA changed the spectrum of the protein in elution peak 1 to that of the apo Q163C/Q309C mutant (Fig 6D), confirming that elution peak 1 contained active αMI-domain bound to ligands through divalent cation mediated interactions.

Discussion

Understanding the interactions between integrins and their ligands is central to the understanding of integrin activities. This is especially true for integrin Mac-1, whose ligands possess diverse structures and physical properties. Although αMI-domain’s interactions with ligands have been studied using X-ray crystallography, the lack of an active αMI-domain suitable for solution NMR has prevented such interactions from being characterized by solution NMR, a powerful and versatile technique that has much to offer in way of characterizing protein-ligand interactions. In this report, we examined five active mutants for their suitability in NMR studies. We were especially interested in mutants that used an intramolecular disulfide bond to constrain the position of the C-terminal α7 helix rather than mutants that disrupted the hydrophobic core of αMI-domain. We thought such an activation mechanism should produce more stable and soluble proteins than strategies that disrupt the hydrophobic core of the protein.

Out of the three disulfide bonded mutants, only the Q163C/Q309C mutant formed the intramolecular disulfide bond spontaneously. Characterization of the protein’s yield, stability, and NMR spectral quality showed the protein was considerably more stable than the ΔK315 and I316G mutants, the two most commonly used active variants of αMI-domain. It also produced superior NMR spectra and has a higher yield than the other two mutants. In addition, Co2+-induced PCS data showed the conformation of the Q163C/Q309C mutant is consistent with active αMI-domain but not inactive αMI-domain. This result is in agreement with SPR data that indicate the Q163C/Q309C mutant has a similar affinity for C3d as the ΔK315 and I316G mutants.

Although treatment with oxidizing agents such as Cu2+/phenanthroline has been shown to induce the formation of an intramolecular disulfide bond in the D132C/K315C mutant, in our hands the treatment also produced several other species that could have resulted from the non-specific oxidation of amino acids such as tyrosine and arginine, a possible factor in the unsuccessful crystallization of the protein after oxidation treatment [11]. It was interesting that the addition of MgCl2 and glutamate, compounds that bind αMI-domain through the MIDAS of active αMI-domain, was able to significantly improve the amount of disulfide bonded D132C/K315C mutant. This shows that stabilizing the protein in the active conformation may help the formation of intramolecular disulfide bonds.

To improve the yield of the Q163C/Q309C mutant, we employed two approaches. First, we examined whether expressing the protein in OrigamiB(DE3), which contains lower levels of the reducing agent glutathione and thioredoxin, increases the fraction of disulfide bonded protein. The result showed OrigamiB(DE3) increased the amount of disulfide bonded protein modestly from ~ 90% to ~ 95%. Second, to remove the remaining protein with no disulfide bond, we leveraged active αMI-domain’s affinity for carboxyl-containing compounds to separate the active fraction from the inactive fraction using CM chromatography. This works well as the reduced protein was not retained in the column. However, a fraction of the active protein was also found in the flow through. One explanation is that, in the presence of MgCl2, inactive αMI-domain may be bound to active αMI-domain because of the latter’s high affinity for glutamate, resulting in a complex incapable of binding the resin. The formation of this inactive-active αMI-domain heterodimer may explain why an equal amount of active αMI-domain was also found in the flow-through fractions. This postulate is corroborated by the observation that a glutamate from one αMI-domain chelated the divalent cation in the MIDAS of another αMI-domain in the crystal structure of the ΔK315 mutant [8]. We think that it may be possible to minimize the amount of disulfide bonded proteins in the flow through if the protein is diluted to a low concentration to prevent the formation of homo-oligomers before applying to the column. Another unexpected outcome is that some of the proteins in the elution are consistent with ligand-bound forms of αMI-domain. It is unclear what the ligand is. One possibility is that the ligand may be contaminating small CM oligosaccharides that were inadvertently extracted by the protein.

Conclusion

The integrin Mac-1 is an important integrin involved in many aspects of leukocyte biology. Understanding the mechanisms of its ligand specificity is essential to developing targeted treatments against Mac-1. However, the lack of a solution NMR suitable active αMI-domain has so far prevented NMR from investigating the interactions of active αMI-domain with its ligands. This report systematically examined five known active mutants of αMI-domain and showed that the Q163C/Q309C mutant adopts the active conformation, can be produced with higher yield, and is more stable than other commonly used active mutants of αMI-domain. The availability of such a mutant will enable more NMR studies of αMI-domain’s interaction with ligands and reveal more insights into the mechanisms of Mac-1 activity.

Supporting information

S1 Fig. Supporting figures and unmodified gel pictures.

(DOCX)

S1 Table. Table of backbone amide hydrogen PCS greater than 0.05 ppm.

(DOCX)

Acknowledgments

We thank Drs. Brian Cherry and Samrat Amin in ASU’s Magnetic Resonance Research Center for maintenance of the NMR instruments. We also want to thank Ms. Shundene Key for performing the thermal shift assays.

Data Availability

Chemical shift assignments of the Mg2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51714. Chemical shifts for the Co2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51716.

Funding Statement

The study was funded by a grant from the National Institutes of Health to XW (www.nih.gov, grant #R01GM118518). NIH did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Luo BH, Carman CV, Springer TA (2007) Structural basis of integrin regulation and signaling. Annu Rev Immunol 25: 619–647. doi: 10.1146/annurev.immunol.25.022106.141618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lamers C, Pluss CJ, Ricklin D (2021) The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. Front Immunol 12: 662164. doi: 10.3389/fimmu.2021.662164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Vorup-Jensen T, Jensen RK (2018) Structural Immunology of Complement Receptors 3 and 4. Front Immunol 9: 2716. doi: 10.3389/fimmu.2018.02716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119: 3901–3903. doi: 10.1242/jcs.03098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rosetti F, Mayadas TN (2016) The many faces of Mac-1 in autoimmune disease. Immunol Rev 269: 175–193. doi: 10.1111/imr.12373 [DOI] [PubMed] [Google Scholar]
  • 6.Bajic G, Yatime L, Sim RB, Vorup-Jensen T, Andersen GR (2013) Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc Natl Acad Sci U S A 110: 16426–16431. doi: 10.1073/pnas.1311261110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fernandez FJ, Santos-Lopez J, Martinez-Barricarte R, Querol-Garcia J, Martin-Merinero H, et al. (2022) The crystal structure of iC3b-CR3 alphaI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor. Nat Commun 13: 1955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee JO, Bankston LA, Arnaout MA, Liddington RC (1995) Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 3: 1333–1340. doi: 10.1016/s0969-2126(01)00271-4 [DOI] [PubMed] [Google Scholar]
  • 9.Xiong JP, Li R, Essafi M, Stehle T, Arnaout MA (2000) An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J Biol Chem 275: 38762–38767. doi: 10.1074/jbc.C000563200 [DOI] [PubMed] [Google Scholar]
  • 10.Lee JO, Rieu P, Arnaout MA, Liddington R (1995) Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80: 631–638. doi: 10.1016/0092-8674(95)90517-0 [DOI] [PubMed] [Google Scholar]
  • 11.McCleverty CJ, Liddington RC (2003) Engineered allosteric mutants of the integrin alphaMbeta2 I domain: structural and functional studies. Biochemical Journal 372: 121–127. doi: 10.1042/BJ20021273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shimaoka M, Lu C, Salas A, Xiao T, Takagi J, et al. (2002) Stabilizing the integrin αM inserted domain in alternative conformations with a range of engineered disulfide bonds. Proceedings of the National Academy of Sciences 99: 16737–16741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Feng W, Nguyen H, Shen D, Deng H, Jiang Z, et al. (2021) Structural Characterization of the Interaction between the alphaMI-Domain of the Integrin Mac-1 (alphaMbeta2) and the Cytokine Pleiotrophin. Biochemistry 60: 182–193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Catanzariti AM, Soboleva TA, Jans DA, Board PG, Baker RT (2004) An efficient system for high-level expression and easy purification of authentic recombinant proteins. Protein Science 13: 1331–1339. doi: 10.1110/ps.04618904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lee W, Bahrami A, Dashti HT, Eghbalnia HR, Tonelli M, et al. (2019) I-PINE web server: an integrative probabilistic NMR assignment system for proteins. J Biomol NMR 73: 213–222. doi: 10.1007/s10858-019-00255-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) Nmrpipe—a Multidimensional Spectral Processing System Based on Unix Pipes. Journal of Biomolecular Nmr 6: 277–293. doi: 10.1007/BF00197809 [DOI] [PubMed] [Google Scholar]
  • 17.Johnson BA (2004) Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol Biol 278: 313–352. doi: 10.1385/1-59259-809-9:313 [DOI] [PubMed] [Google Scholar]
  • 18.Orton HW, Huber T, Otting G (2020) Paramagpy: software for fitting magnetic susceptibility tensors using paramagnetic effects measured in NMR spectra. Magn Reson 1: 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Vorup-Jensen T, Carman CV, Shimaoka M, Schuck P, Svitel J, et al. (2005) Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci U S A 102: 1614–1619. doi: 10.1073/pnas.0409057102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, et al. (2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 332: 153–159. doi: 10.1016/j.ab.2004.04.031 [DOI] [PubMed] [Google Scholar]
  • 21.Michishita M, Videm V, Arnaout MA (1993) A novel divalent cation-binding site in the A domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 72: 857–867. doi: 10.1016/0092-8674(93)90575-b [DOI] [PubMed] [Google Scholar]
  • 22.Otting G (2010) Protein NMR using paramagnetic ions. Annu Rev Biophys 39: 387–405. doi: 10.1146/annurev.biophys.093008.131321 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Matteo De March

24 Oct 2022

PONE-D-22-26948The Q163C/Q309C Mutant of αMI-domain is an Active Variant Suitable for NMR CharacterizationPLOS ONE

Dear Dr. X. Wang,

Thank you for submitting your manuscript to PLOS ONE. As you can see below both Reviewers agree on the good impact of your manuscript that is well and clearly presented.However, they highlight some minor points that require improvement prior to acceptance.Please note that, in particular, it would be very appreciated if your experimental data will be deposited and a full account of data analysis process with representative HNCACB and HNCOCACB spectra will be included as supplementary material.

Please submit your revised manuscript by December 8, 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind Regards

Matteo De March

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was supported by funding from NIH/NIGMS (R01GM118518). We thank Drs. Brian Cherry and Samrat Amin in ASU’s Magnetic Resonance Research Center for maintenance of the NMR instruments.”

We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The study was funded by a grant from the National Institutes of Health to XW (www.nih.gov, grant #R01GM118518). NIH did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in your Competing Interests section: 

“NO authors have competing interests”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript is an elegant example of rational engineering to retain function, and enable structural/physical analysis. The goal is to study an ligand-binding domain of an integrin, in the active state. Previous work proposes mutations to "stabilize" the domain, but here it is shown that such mutations do not stabilize the domain. The authors propose new mutations that would lead to an active state whereby they would stabilize with an intramolecular disulphide. All the data presented supports the conclusion of a stable active domain, although it requires glutamate/Mg2+ to maintain a state suitable for NMR analysis. The paper is well written, figures are clear. The only issue is a description of the Co+-induced pseudocontact shifts are based on the assignments. I would like these assignments to be deposited in the BMRB or if you have state the accession number. I consider this important as the BMRB will assess the quality (accuracy) of assignment. I do agree the fitting of the PCS is convincing that all is good, but you need to deposit the data.

Reviewer #2: This very clearly written and presented MS makes a strong and logically argued case for the use of an engineered domain, from a key integrin (CR3), for ligand-binding and screening studies, and in particular for studies using NMR spectroscopy. The modified domain has two non-native cysteines that form a disulfide bond, presumably stabilising an active conformation of the domain that is able to bind ligands (unlike the wild type domain) via a MIDAS motif. Because of the many reported ligands for this domain and its well-established central role in immune responses, the topic is of quite wide interest.

It would be good to show (eg in supplementary) the position of the mutated residues and perhaps a predicted structure of the disulfide-containing molecule.

Readers might be a little sceptical of how the authors were able to assign the amide nitrogens and protons for this mutant given the sub-optimal nature of the HSQC spectrum that contains many, well dispersed but very small peaks but also a region of more intense and overlapping peaks in the random-coil region. To reassure us, they should include in supplementary data a full account of this process including a method section and representative HNCACB and HNCOCACB spectra, and information regarding the extent of 15NH assignments (that should be deposited in a database) for both Mg and Co forms.

Another improvement to this MS would be to include some KD values based on SPR studies using a dilution series of their domains (binding to immobilised C3d). The authors seem to have plenty of sample for the binding partners and access to the kit so it is puzzling why they have not already included such measurements. It looks like the alpha-helix truncation mutant might bind to C3d more tightly than the double-Q (disulfide) mutant since it has a slower off-rate. That does not really weaken their conclusions but is good to know.

Small things:

Understanding.... is... (not are)

Data are... (not is)

And they seem to use the terms intracellular and intramolecular indiscriminately - I think they mean intermolecular (?)

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Paul N Barlow

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jan 25;18(1):e0280778. doi: 10.1371/journal.pone.0280778.r002

Author response to Decision Letter 0


8 Dec 2022

Reviewer #1: This manuscript is an elegant example of rational engineering to retain function, and enable structural/physical analysis. The goal is to study an ligand-binding domain of an integ-rin, in the active state. Previous work proposes mutations to "stabilize" the domain, but here it is shown that such mutations do not stabilize the domain. The authors propose new mutations that would lead to an active state whereby they would stabilize with an intramolecular disulphide. All the data presented supports the conclusion of a stable active domain, although it requires gluta-mate/Mg2+ to maintain a state suitable for NMR analysis. The paper is well written, figures are clear. The only issue is a description of the Co+-induced pseudocontact shifts are based on the assignments. I would like these assignments to be deposited in the BMRB or if you have state the accession number. I consider this important as the BMRB will assess the quality (accuracy) of assignment. I do agree the fitting of the PCS is convincing that all is good, but you need to de-posit the data.

Reply: The chemical shifts of both the Mg2+ and Co2+ species of the Q163C/Q309C bound to glutamate have been deposited with BMRB. The accession numbers are 51714 for the Mg2+ spe-cies and 51716 for the Co2+ species. A detailed description of the assignment process is also in-cluded in the manuscript (lines 162 to 173). In particular, the Mg2+ species were assigned with HNCACB and HNCOCACB using conventional methods. To assign the Co2+ species, we used HNCACB and HNCOCACB of the Co2+ sample and the fact that PCS values are similar for am-ide hydrogen and nitrogen pairs if the atoms are not very close to the paramagnetic center to pre-dict possible assignments. The proposed assignments were verified using CA and CB chemical shifts.

Reviewer #2: This very clearly written and presented MS makes a strong and logically argued case for the use of an engineered domain, from a key integrin (CR3), for ligand-binding and screening studies, and in particular for studies using NMR spectroscopy. The modified domain has two non-native cysteines that form a disulfide bond, presumably stabilising an active con-formation of the domain that is able to bind ligands (unlike the wild type domain) via a MIDAS motif. Because of the many reported ligands for this domain and its well-established central role in immune responses, the topic is of quite wide interest.

It would be good to show (eg in supplementary) the position of the mutated residues and perhaps a predicted structure of the disulfide-containing molecule.

Reply: Models of the disulfide bond mutants have been added to the supporting information (Figure 1 in S1 figures).

Readers might be a little sceptical of how the authors were able to assign the amide nitrogens and protons for this mutant given the sub-optimal nature of the HSQC spectrum that contains many, well dispersed but very small peaks but also a region of more intense and overlapping peaks in the random-coil region. To reassure us, they should include in supplementary data a full account of this process including a method section and representative HNCACB and HNCOCACB spec-tra, and information regarding the extent of 15NH assignments (that should be deposited in a database) for both Mg and Co forms.

Reply: We apologize for neglecting to mention the details of our assignment process. In particu-lar, we hope we have not given the false impression that all residues in the two metal-bound forms were assigned. Because our goal is to validate the structure, we only obtained enough as-signments to allow the evaluation of the structure of the Q163C/Q309C mutant. As for the quali-ty of the spectra, 3D spectra were collected using samples containing 1 mM divalent cation and 10 mM glutamate. These ligands significantly improved the spectral quality of the Q163C/Q309C mutant. This was mentioned in the methods section, and now we also added the detail to the results section. The samples were also deuterated to reduce relaxation and increase intensity. We have included projections of the HNCACB and HNCOCACB data in the support-ing information (Figure 3 in S1 figure). Assignments have also been deposited with BMRB (ac-cession code 51714 for the Mg2+ species and 51716 for the Co2+ species). A detailed description of the assignment process has been included in the methods section (lines 162 to 173). In total, 77 residues out of 186 non-proline residues in the Mg2+ form were assigned. Out of these 77 res-idues, 56 residues in the Co2+ form were assigned, 38 of which had HN PCS greater than 0.05 ppm.

Another improvement to this MS would be to include some KD values based on SPR studies us-ing a dilution series of their domains (binding to immobilised C3d). The authors seem to have plenty of sample for the binding partners and access to the kit so it is puzzling why they have not already included such measurements. It looks like the alpha-helix truncation mutant might bind to C3d more tightly than the double-Q (disulfide) mutant since it has a slower off-rate. That does not really weaken their conclusions but is good to know.

Reply: We were unable to include full titration series for these active variants in our initial manu-script because non-specific interactions of active mutants with the sensor prevented the inclusion of data acquired with higher concentrations of the mutants. We have repeated these SPR experi-ments with lower concentrations of mutants and the data are now included in the manuscript. Kds obtained from equilibrium values of the responses at different concentrations showed the affinities of these mutants for C3d are similar and in agreement with reported values (lines 255-269, Figure 3). These data also confirmed what the reviewer already noted, that is the dissocia-tion rate of the ΔK315 mutant is slower than the other mutants. However, we were not able to obtain good fittings of the association and dissociation phases to calculate the actual rates.

Small things:

Understanding.... is... (not are)

Data are... (not is)

And they seem to use the terms intracellular and intramolecular indiscriminately - I think they mean intermolecular (?)

Reply: We have carefully gone through the manuscript to correct all grammatical mistakes we can find. All mentions of “intracellular” have been replaced with “intramolecular”.

Attachment

Submitted filename: Response-v1.1.docx

Decision Letter 1

Matteo De March

4 Jan 2023

PONE-D-22-26948R1

The Q163C/Q309C Mutant of αMI-domain is an Active Variant Suitable for NMR Characterization

PLOS ONE

Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 18 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org.When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We look forward to receiving your final version soon.

With Best Regards,

Matteo De March

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor comments:

your manuscript can be now accepted as both Reviewers agreed with the revised version. However, Reviewer 2 stated "1 AU = 1 pg per mm2 (square mm)". Although it is a very small change, it cannot be ignored.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed comments and questions of the review. The deposition of data to the BMRB is important.

Reviewer #2: The authors have addressed my concerns but please correct statement regarding SPR. You say 1 AU = 1 pg per mm. This should of course be 1 pg per mm2 (square mm)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Paul Nigel Barlow

PLoS One. 2023 Jan 25;18(1):e0280778. doi: 10.1371/journal.pone.0280778.r004

Author response to Decision Letter 1


6 Jan 2023

Reviewer #1: The authors have addressed comments and questions of the review. The deposition of data to the BMRB is important.

Response: Thank you for your review.

Reviewer #2: The authors have addressed my concerns but please correct statement regarding SPR. You say 1 AU = 1 pg per mm. This should of course be 1 pg per mm2 (square mm)

Response: Thank you for noticing the mistake in the unit. We have changed it to “1 pg / mm2” (line 149).

Attachment

Submitted filename: Response2.docx

Decision Letter 2

Matteo De March

10 Jan 2023

The Q163C/Q309C Mutant of αMI-domain is an Active Variant Suitable for NMR Characterization

PONE-D-22-26948R2

Dear Prof. X. Wang,

we are pleased to inform you that your manuscript is now ready for publication. Within one week, you’ll receive an e-mail detailing the outstanding technical requirements that need to be addressed before scheduling your publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

I would like to wish you all the best for your work.

Kind regards.

Matteo De March

Academic Editor

PLOS ONE

Acceptance letter

Matteo De March

16 Jan 2023

PONE-D-22-26948R2

The Q163C/Q309C Mutant of αMI-domain is an Active Variant Suitable for NMR Characterization

Dear Dr. Wang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Matteo De March

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Supporting figures and unmodified gel pictures.

    (DOCX)

    S1 Table. Table of backbone amide hydrogen PCS greater than 0.05 ppm.

    (DOCX)

    Attachment

    Submitted filename: Response-v1.1.docx

    Attachment

    Submitted filename: Response2.docx

    Data Availability Statement

    Chemical shift assignments of the Mg2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51714. Chemical shifts for the Co2+ species of the Q163C/Q309C mutant have been deposited in the BMRB with the BMRB ID 51716.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES